TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic or cytologic diagnosis non-small cell lung cancer (NSCLC) (Stage IIIB or IV)~* Have not received any prior chemotherapy, molecular therapy, immunotherapy, biological therapy, or radiotherapy. Exception: palliative radiotherapy that is completed at least 4 weeks prior to study enrolment.~* Have 'never smoked' (defined as having smoked \<100 cigarettes during his/her lifetime)~* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1~Exclusion Criteria:~* Concurrent administration of any other tumor therapy~* Other co-existing malignancies~* Pregnancy or breast feeding~* Serious concomitant disorders~* Inability or unwillingness to take folic acid or vitamin B12 supplementation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed/Cisplatin/Gefitinib (Type: EXPERIMENTAL): Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity.
- Pemetrexed/Cisplatin (Type: EXPERIMENTAL): Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by pemetrexed 500 mg/m2 administered by IV infusion (with optional cisplatin 75 mg/m2 for up to 2 additional cycles) until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Children eligible to be enrolled in the study are those whose parents provide written informed consent, and are in generally good health based on the clinical judgment of the investigators.~* Group 1 and 2 (Follow up) subjects must be 40 +/- 3 months of age at the time of enrollment and participated in the original V59P14 study (NCT00474526).~* Group 3 and 4 (Naïve) subjects must be healthy, meningococcal vaccine-naïve children ages 40 +/- 3 months (Group 3) or 60 +/-3 months (Group 4) at the time of enrollment, respectively.~Exclusion Criteria:~* Serious, acute, or chronic illnesses are reasons for exclusion.~* Subjects who have received any vaccine (excluding influenza vaccines) 28 days preceding enrollment visit. Influenza vaccines (including FluMist®) are excluded for the 14 days prior to the enrollment visit.~* Subjects who have received any meningococcal vaccine since birth (Groups 3 \& 4 -naive) or last study dose in V59P14 (NCT00474526) trial (Groups 1 \& 2 - follow on).

- Gender: ALL
- Minimum Age: 37 Months
- Maximum Age: 63 Months
- Healthy Volunteers: t

Study Arms:
- ACWY - 4 (Type: EXPERIMENTAL): Subjects who had previously received 4 doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in the parent study during their first year of life are administered one booster dose of the same vaccine at 60 months of age.
- ACWY - 2 (Type: EXPERIMENTAL): Subjects who had previously received 1 or 2 doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in the parent study during their second year of life, are administered one booster dose of the same vaccine at 60 months of age.
- Naïve - 40 (Type: OTHER): Control subjects, age-matched with the intervention groups subjects (40 months of age), to receive 1 optional dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
- Naïve - 60 (Type: ACTIVE_COMPARATOR): Control subjects, age-matched with the intervention groups subjects (60 months of age), are administered one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Diabetes type 2, detectable C-peptide, HbA1c 7-10%~2. Pretreatment with basal insulin +/- Metformin or/and +/- Pioglitazone 3 Age \> 18 years, BMI \<= 45 kg/m2~Exclusion criteria:~1. Uncontrolled hyperglycemia during Run-in~2. Myocardial infarction, stroke or TIA within 3 months prior to informed consent~3. Liver impairment; gastric surgery; medical history of cancer in last 5 years~4. Other antidiabetic drugs, antiobesity drugs, systemic steroids, other investigational drug before randomisation~5. Unsufficient birth control, pregnancy and nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Linagliptin (Type: EXPERIMENTAL): patient receives a tablet with intended final marketed dose
- Placebo (Type: PLACEBO_COMPARATOR): patient receives a tablet identical to those containing Linagliptin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Glycemic Control in Adults With Type 1 Diabetes When Switching to Insulin Degludec

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* People with T1D ≥18 years at the moment of switch to Insulin Degludec~* Diagnosed with T1D ≥2 years before switch to Insulin Degludec~* On basal-bolus insulin therapy with insulin pens ≥2 years before switch to Insulin Degludec~* ≥6 months use of Insulin Degludec at moment of datacollection~* Using continuous glucose monitoring ≥2 years before switch to Insulin Degludec~Exclusion Criteria:~* People with T1D \<18 years at the moment of switch to Insulin Degludec~* People without T1D or with T1D \<2 years before switch to Insulin Degludec~* Women with T1D who are pregnant or planning pregnancy during -12 and +12 months~* Not using basal-bolus insulin therapy with insulin pens during -24 and +6 months~* Start to use non-insulin antidiabetic agents between -12 and +12 months~* Having received treatment with oral or injectable corticosteroids during -12 and +12 months~* Undergoing hemodialysis, renal transplantation, or beta cell transplantation during -12 and +12 months~* \<6 months use of Insulin Degludec at moment of datacollection~* Not using continuous glucose monitoring or \<2 years before switch to Insulin Degludec

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study cohort (Type: None): People with type 1 diabetes who switched to Insulin Degludec from another basal insulin between 1/5/2019 and 1/6/2021 in the two participating sensors

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-65years.~2. Obese BMI \>30kg/m2~3. LDL cholesterol \>100 mg/dl~4. Written and informed consent signed and dated 5. Not on any vitamin/antioxidants~Exclusion Criteria:~1. On any antilipid agents.~2. Triglyceride \>500mg/dl~3. Myocardial infarction, angioplasty/stent placement or coronary artery bypass surgery in the past 6 months~4. Patient on chronic use of non-steroidal anti-inflammatory drugs or steroids~5. Hepatic disease~6. Renal impairment~7. History of drug or alcohol abuse~8. Participation in any other concurrent clinical trial~9. Use of an investigational agent or therapeutic regimen within 30 days of study.~10. Smoker~11. Pregnancy~12. Premenopausal women who are not on birth control pills and have not had a hysterectomy or tubal ligation 13. Anemia with hemoglobin \<12 g/dl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Placebo Arm (Type: PLACEBO_COMPARATOR): Obese subjects treated with placebo for 6 weeks
- Vytorin Arm (Type: ACTIVE_COMPARATOR): Obese subjects treated with Vytorin for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* must have completed 24 weeks of dosing of the CL0600-020 study~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- teduglutide (Type: EXPERIMENTAL): 0.05 mg/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Interventional Study for Patient With Cancer Pain to Evaluate the Efficacy and Safety of OxyNorm® Compared to Morphine Sulfate Through the IV Continuous Infusion.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult men and women aged 19 years or more~2. Patients with cancerous pain who are hospitalized or scheduled for hospitalization at Screening and not planned to be discharged during the study~3. Patients with mean moderate to severe pain over the past 7 days at Screening as verbally confirmed (NRS 4 or higher)~4. Subjects who voluntarily signed the Informed Consent Form for the study~5. Subjects who are capable of understanding details of the study and verbal communication on pain intensity~Exclusion Criteria:~1. Patients who reached the narcotic analgesic dose corresponding to the followings for cancerous pain treatment immediately prior to Screening (oral morphine dose 195mg/day, oral oxycodone dose 130mg/day, patch fentanyl dose 75μg/hour)~2. Patients with a medical history of hypersensitivity to an ingredient of oxycodone hydrochloride or morphine sulfate or other narcotic analgesics~3. Patients who have contraindications and cautions when study drugs administered.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oxycodone Hydrochloride (Type: EXPERIMENTAL): Brand Name: OxyNorm® Generic name: Oxycodone hydrochloride
- Morphine Sulphate (Type: ACTIVE_COMPARATOR): Brand name: BC Morphine sulfate Generic name: Morphine sulfate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Healthy volunteers, between 18 and 45 years of age~* Normal laboratory (blood test) results~Key Exclusion Criteria:~* Prior immunization with anthrax vaccine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- AVP-21D9 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phentolamine Mesylate as a Reversal of Local Anesthesics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Previously diagnosticated to receive dental treatment according to Leonformacion's criteria~Exclusion Criteria:~* Hepatic or renal patient~* Fertility treatment, pregnancy or lactation~* Treatment with oral anticoagulants~* Patients with known allergies to anesthetics, excipients or phentolamine mesylate~* Patients with previous facial paresthesia~* Patients who had taken any painkiller or anti-inflammatory the day before~* Patients in which the anesthetic technique fails or has to be reinforced with more than two carpules

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- lidocaine (Type: EXPERIMENTAL): lidocaine 2% 1:80000
- articaine (Type: EXPERIMENTAL): articaine 4% 1:200000
- bupivacaine (Type: EXPERIMENTAL): bupivacaine 0,5% 1:200000

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine for Acute Post-mastectomy Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult females scheduled for unilateral MRM with axillary evacuation for breast cancer,~* American Society of Anesthesiologists physical status (ASA) class I and II~Exclusion Criteria:~* Patients with a known allergy to Duloxetine or morphine,~* A history of drug or alcohol abuse,~* Patients with impaired kidney or liver functions,~* Patients with chronic pain or regularly receiving analgesics,~* Any psychiatric illness that would interfere with the perception and the assessment of pain.~* Any reason that resulted in the protocol violation.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- placebo group (Type: PLACEBO_COMPARATOR): None
- duloxetine 30 (Type: ACTIVE_COMPARATOR): None
- duloxetine 60 (Type: ACTIVE_COMPARATOR): None
- duloxetine 90 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Longitudinal Follow-up of High School Athletes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Elite athletes from the elite sport school in Wilrijk and Leuven~* First grade of high school~Exclusion Criteria:~* Performing \>4hours/week sports

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- Football players (Type: None): Football players of the first grade of high school are recruited from the topsportschool in Leuven.
- Basketball players (Type: None): Basketball players of the first grade of high school are recruited from the topsportschool in Leuven.
- Swimmers (Type: None): Swimmers of the first grade of high school are recruited from the future team of the Flemish Swimming Federation
- Control group (Type: None): Age-matched controls are recruited (exercising at a recreational level, \>4 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* Satisfying International Classification of Disease-10 (ICD) diagnostic criteria of schizophrenia;~* Positive and Negative Syndrome Scale (PANSS) total score ≥ 60~Exclusion criteria:~* Refractory schizophrenia or Patients treated with sufficient clozapine for a minimum period of 6-8 weeks without improvement;~* Participation into another clinical trial within the last month;~* Patients previously or currently treated with amisulpride;~* Patients receiving clozapine within the past 1 month or treated with long-acting formulation of antipsychotic medication within the past 2 months;~* Patients receiving electric convulsive therapy or physical therapy within the past 1 month;~* Patients with coexisting severe systemic diseases;~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Amisulpride (Type: EXPERIMENTAL): Patients are treated with Amisulpride referring to the dosage and usage section in Chinese Solian® PI. Amisulpride dosage is adjusted based on individual response and reaches the sufficiency within 1 week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of chronic lymphocytic leukemia requiring therapy~* Previously treated with ≥ 1 chemotherapeutic regimen~PATIENT CHARACTERISTICS:~* WHO performance status 0-2~* Life expectancy ≥ 12 weeks~* Creatinine clearance ≥ 30 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile female patients must use effective contraception for 4 weeks before, during, and for 6 months after completion of study treatment~* Fertile male patients must use effective contraception during and for 6 months after completion of study treatment~* No history of anaphylaxis after exposure to rat or mouse-derived complementary-determining region (CDR)-grafted humanized monoclonal antibodies~* No toxicity attributable to purine analogues (e.g., autoimmune hemolytic anemia, neurological toxicity, or allergy)~* No active infection~* No other severe (particularly cardiac or pulmonary) diseases or mental disorders that would preclude study participation~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior fludarabine (or other purine analogues) combined with cyclophosphamide and mitoxantrone hydrochloride~* No prior rituximab, either alone or in combination with chemotherapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have plaque psoriasis despite at least 4 months of treatment with etanercept per current product labeling~* Have psoriatic target lesions that have a PGA score greater than 1 (minimal) at screening~* If receiving methotrexate at screening, must have received methotrexate for at least 3 months and at a stable dose of \<= 25 mg/week for at least 4 weeks prior to screening~* If receiving cyclosporine at screening, must have received cyclosporine at a stable dose of \<= 5 mg/kg daily for at least 4 weeks prior to screening.~Exclusion Criteria:~* Have already received infliximab or adalimumab~* Have shown a previous immediate hypersensitivity response, including anaphylaxis, to an immunoglobulin product~* Have a history of latent or active granulomatous infection, including tuberculosis, histoplasmosis, or coccidioidomycosis, prior to screening~* Have a concomitant diagnosis or any history of Congestive Heart Failure~* Are pregnant, nursing, or planning pregnancy~* Have used systemic corticosteroids within the 4 weeks prior to screening~* Have used topical corticosteroids or have initiated treatment with other topical therapies that could affect psoriasis or Psoriasis Area and Severity Index (PASI) evaluation (e.g., tar, anthralin, calcipotriene, tazarotene, methoxsalen) within 2 weeks prior to screening~* Have used new systemic agents/treatments, other than methotrexate, that can affect psoriasis including, but not limited to, immunosuppressants and/or psoralen plus ultraviolet A light (PUVA) within the 4 weeks prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): infliximabOpen-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete